NEW YORK, May 3 (GenomeWeb News) - Cellectricon and AstraZeneca will "study the possibility" of developing a new cell-based microfluidic screening platform, Cellectricon said today.
Registering provides access to this and other free content.
Already have an account?Login Now.
Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.
Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.
The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.
In Science this week: genetically modified flu virus could be key to new live vaccines, and more.